Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma

Part of paid clinical trials in Washington D.C., District of Columbia.

Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study ID
NCT06796543
Status
Recruiting
Apply to this trial

Conditions

  • Ewing Sarcoma
  • Metastatic Sarcoma
  • Radiation Therapy Patient
  • Rhabdomyosarcoma

Eligibility Criteria

Sex
ALL
Age
N/A - 39 Years
Healthy Volunteers
Not accepted

Interventions

  • Consolidative radiation therapy (cRT) — RADIATION
    Treatment that is given after cancer has disappeared following the initial therapy. Consolidation therapy is used to kill any cancer cells that may be left in the body. It may include radiation therapy, a stem cell transplant, or treatment with drugs that kill cancer cells. Also called intensification therapy and postremission therapy.

Study Details

This study is designed for children, adolescents and young adults undergoing radiation therapy for metastatic sarcoma. The aim of the study is to investigate if the investigators can improve the overall survival of these patients by targeting metastatic sites with radiation.

Key Dates

Start date
Mar 25, 2025
Status verified
Apr 2026
Primary completion
Mar 31, 2028
Completion
Mar 31, 2030

Study Design

Enrollment
70 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE

Arms

  • Experimental: Consolidative radiation therapy (cRT)
    The therapeutic intervention in Stratum A is consolidative radiation therapy (cRT), which is defined as radiation/surgery to the primary site and radiation to all sites of metastatic disease. All patients enrolled in stratum A will receive standard of care (SOC) induction chemotherapy followed by restaging imaging prior to delivery of cRT.
  • No Intervention: standard of care (SOC)
    Patients in Stratum B will undergo standard of care (SOC) second line systemic therapy with radiation to at least one disease site.

Primary Outcome Measure

Event free survival [ Time Frame: 2 years ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Sibley Memorial HospitalWashington D.C.District of Columbia20016
Sahaja Acharya, MD
[email protected]
443-287-7889
Ethan Arnone, BS
[email protected]
2029192533
Sahaja Acharya, MD (PRINCIPAL_INVESTIGATOR)
Johns Hopkins HospitalBaltimoreMaryland21287
Sahaja Acharya, MD
[email protected]
443-287-7889
Ethan Arnone, BS
[email protected]
2029192533
Sahaja Acharya, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Washington D.C., DC

By research site
Sibley Memorial Hospital· Washington D.C., DCJohns Hopkins Hospital· Baltimore, MD

Related Studies